Funder
H2020 Marie Skłodowska-Curie Actions
Instituto de Salud Carlos III
Consejería de Educación
Juventud y Deporte
Comunidad de Madrid
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference24 articles.
1. European Medicines Agency. VFEND, INN voriconazole, Annex I, Summary of Product Characteristics [cited 31 Oct 2019]. 2019. https://www.ema.europa.eu/en/documents/product-information/vfend-epar-product-information_en.pdf.
2. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649–63.
3. Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38:25–31.
4. Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36:1119–25.
5. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos Biol Fate Chem. 2003;31:731–41.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献